NGeneBio Co

NGeneBio Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of NGeneBio Co (354200.KQ) as of Nov 17, 2026 is 0.07. In the previous year, Long-Term Debt to Equity Ratio was 0.01 — a change of 711.41% (higher).

LT Debt/Equity

0.07

YoY

711.41%

Last updated:

Long-Term Debt to Equity Ratio of NGeneBio Co is 2024 0.07 . Long-Term Debt to Equity Ratio of NGeneBio Co was 2023 0.01 . It decreases by 711.41% higher compared to the previous year.

The NGeneBio Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
-0.13 KRW
Jan 1, 2019
0.11 KRW
Jan 1, 2020
0.00 KRW
Jan 1, 2021
0.02 KRW
Jan 1, 2022
0.01 KRW
Jan 1, 2023
0.01 KRW
Jan 1, 2024
0.07 KRW
The NGeneBio Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.07+711.41%
0.01-39.13%
0.01-13.59%
0.02+467.11%
0.00-97.37%
0.11-188.02%
-0.13—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NGeneBio Co Stock analysis

What does NGeneBio Co do? NGeneBio Co., Ltd. generates revenue through the development and sale of diagnostic products for cancer-related genetic testing. The company offers BRCAaccuTest for hereditary breast and ovarian cancer, HEMEaccuTest for blood cancer gene testing including leukemia and lymphoma, and SOLIDaccuTest for solid cancer tissues like lung and colon cancer. Additional products include HLAaccuTest for bone marrow transplantation antigen testing, ONCOaccuPanel for large-capacity solid cancer diagnosis, and HEREDaccuTest for rare disease diagnosis. The firm also provides direct-to-consumer genetic testing and personalized healthcare services, targeting healthcare providers, hospitals, and individual consumers seeking genetic insights. The company's product portfolio serves medical institutions and patients requiring precise genetic diagnostics. HEMEaccuTest specifically addresses blood cancer types such as leukemia and lymphoma, while SOLIDaccuTest covers common solid cancers including lung and stomach cancer. ONCOaccuPanel supports comprehensive solid cancer diagnosis, and HEREDaccuTest caters to rare disease diagnostics. These products are sold to healthcare facilities and offered directly to consumers through DTC services. NGeneBio's revenue streams include sales of diagnostic kits and services, with a focus on cancer-related genetic testing. The BRCAaccuTest, HEMEaccuTest, and SOLIDaccuTest products are central to its business, targeting both clinical and direct consumer markets. Personalized healthcare services complement the product offerings, enhancing customer engagement and recurring revenue opportunities. NGeneBio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NGeneBio Co stock

Long-Term Debt to Equity Ratio of NGeneBio Co is 0.07 in 2024.

Long-Term Debt to Equity Ratio of NGeneBio Co changed from 0.01 to 0.07, representing a 711.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio NGeneBio Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's NGeneBio Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — NGeneBio Co

All Key Metrics — NGeneBio Co